Salud financiera de hoja de balance de Immuron

Salud financiera controles de criterios 6/6

Immuron tiene un patrimonio de los accionistas total de A$17.5M y una deuda total de A$0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son A$19.9M y A$2.4M respectivamente.

Información clave

Ratio deuda-patrimonio

AU$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	AU$16.42m
Patrimonio	AU$17.53m
Total pasivo	AU$2.36m
Activos totales	AU$19.88m

Actualizaciones recientes sobre salud financiera

Recent updates

We're Not Very Worried About Immuron's (ASX:IMC) Cash Burn Rate

Mar 08

We Think Immuron (ASX:IMC) Can Afford To Drive Business Growth

Jan 20

We Think Immuron (ASX:IMC) Can Afford To Drive Business Growth

Oct 01

We Think Immuron (ASX:IMC) Can Afford To Drive Business Growth

Mar 30

Have Insiders Been Selling Immuron Limited (ASX:IMC) Shares This Year?

Feb 05

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (A$18.9M) de IMC superan a sus pasivos a corto plazo (A$2.2M).

Pasivo a largo plazo: Los activos a corto plazo de IMC (A$18.9M) superan a sus pasivos a largo plazo (A$132.3K).

Historial y análisis de deuda-patrimonio

Nivel de deuda: IMC está libre de deudas.

Reducción de la deuda: IMC no tenía deudas hace 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: IMC tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.

Pronóstico de cash runway: IMC dispone de suficiente cash runway para 2.6 años si el flujo de caja libre sigue creciendo a tasas históricas de 5.1% cada año.

Salud financiera de hoja de balance de Immuron

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

We're Not Very Worried About Immuron's (ASX:IMC) Cash Burn Rate

We Think Immuron (ASX:IMC) Can Afford To Drive Business Growth

We Think Immuron (ASX:IMC) Can Afford To Drive Business Growth

We Think Immuron (ASX:IMC) Can Afford To Drive Business Growth

Recent updates

We're Not Very Worried About Immuron's (ASX:IMC) Cash Burn Rate

Immuron Limited Announces Positive Results Support Travelan Progress to Phase 3 Clinical Trials in the US

Immuron Limited Clinical Trials Update

Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study

Immuron Limited, Annual General Meeting, Nov 21, 2023

Immuron Limited Announces Travelan® Clinical Study Cohort 2 Commences

Full year 2023 earnings released: AU$0.017 loss per share (vs AU$0.013 loss in FY 2022)

Full year 2023 earnings released: AU$0.017 loss per share (vs AU$0.013 loss in FY 2022)

Immuron Limited Announces First Patients Enrolled in Travelan® Clinical Study

Immuron Limited Initiates Recruitment of Travelan Clinical Study

Immuron Limited Announces US Food and Drug Administration Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves Way for Clinical Trial Initiation

First half 2023 earnings released: AU$0.009 loss per share (vs AU$0.008 loss in 1H 2022)

Immuron US DoD Naval Medical Research Center Responds to FDA Clinical Hold for New Campylobacter ETEC Therapeutic

Immuron Limited Receives FDA Approval for Travelan IND Application

Immuron Limited Submits IND Application To FDA for Travelan

Insufficient new directors

Immuron Limited, Annual General Meeting, Oct 28, 2022

Full year 2022 earnings released: AU$0.013 loss per share (vs AU$0.038 loss in FY 2021)

Immuron Limited Provides Update on IMM-124E SARS-CoV-2 Research

Immuron Limited Provides Update on IND Application for Campylobacter ETEC Therapeutic

Immuron US DoD Naval Medical Research Center Submits IND Application for New Campylobacter ETEC Therapeutic

Immuron Limited Provides Update on the Planned Clinical Trial to Evaluate the Efficacy of Travelan and Two Third Party Non-Antibiotic Products in Travelers' Diarrhea

Immuron Limited Appoints Steven Lydeamore as Chief Executive Officer, effective June 27, 2022

Insufficient new directors

Immuron Limited Announces Work on the Investigational New Drug Application to Evaluate the Efficacy of A Single Dose Regimen of Travelan

First half 2022 earnings: Revenues and EPS in line with analyst expectations

We Think Immuron (ASX:IMC) Can Afford To Drive Business Growth

Full year 2021 earnings released: AU$0.038 loss per share (vs AU$0.017 loss in FY 2020)

Executive Vice Chairman Peter Anastasiou has left the company

We Think Immuron (ASX:IMC) Can Afford To Drive Business Growth

Insufficient new directors

Immuron Limited Provides Monash University Research Update on SARS-CoV-2 Program

We Think Immuron (ASX:IMC) Can Afford To Drive Business Growth

First half 2021 earnings released: AU$0.026 loss per share (vs AU$0.009 loss in 1H 2020)

Have Insiders Been Selling Immuron Limited (ASX:IMC) Shares This Year?

New 90-day low: AU$0.21

New 90-day low: AU$0.21

Immuron Limited Provides Update on Progress of the Anti-Viral Activity of IMM-124E

Immuron Limited Announces That the Naval Medical Research Center Has Completed the Characterisation of the Colostrum Harvested from Cows Immunized with the Experimental Vaccine Developed to Target Campylobacter and Enterotoxigenic E.Coli

Immuron Limited Announces US DoD NMRC Reports Positive Response to Vaccine

New 90-day low: AU$0.23

Immuron Limited Provides Shareholders and the Market with an Update on the Planned Clinical Programs in Travelers’ Diarrhea

Full year earnings released - AU$0.017 loss per share

Immuron Limited has completed a Follow-on Equity Offering in the amount of $20.000025 million.

New 90-day high - AU$0.85

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera